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Background:Most literature on second primary cancers (SPCs) focuses on possible factors,
which may increase the risk of these cancers, and little attention has been paid for the overall
incidence differences between first primary cancers (FPCs) and same SPCs. We wanted to
compare the incidence rates for all common cancers when these were diagnosed as FPCs and
SPCs after invasive and in situ squamous cell carcinoma (SCC) of the skin, which are usually
treated by surgery only.
Methods: Cancers were identified from the Swedish Cancer Registry from the years 1990
through to 2015, and they included, in addition to skin cancers, 20 male cancers totaling
484,850 patients and 22 female cancers totaling 452,909 patients. Standardized incidence
rates and relative risks (RRs) were calculated for sex-specific common cancers as FPC and as
SPC after skin SCC. Spearman rank correlations were used in the analysis of incidence
ranking of FPC and SPC.
Results: Of total, 29,061 men and 23,533 women developed invasive SCC and 27,842 men
and 36,383 women in situ SCC. The total number of 20 other male cancers was 484,850 and
of 22 female cancers it was 452,909. Rank correlations ranged from 0.90 to 0.96 (P~5×10−6),
indicating that overall skin SCC did not interfere with SPC formation. The exceptions were
increased SPC risks for melanoma, sharing risk factors with skin SCC, and non-Hodgkin and
Hodgkin lymphoma, and cancers of the upper aerodigestive tract, connective tissue, and male
and female genitals suggesting contribution by skin cancer initiated immune dysfunction.
Conclusion: The incidence ranking of SPCs after skin cancers largely follows the incidence
ranking of FPCs indicating that overall skin SCC does not greatly interfere with the intrinsic
carcinogenic process. The main deviations in incidence between FPC and SPC appeared to
be due to shared risk factors or immunological processes promoting immune responsive
cancer types.
Keywords: skin cancer, second cancer, first primary cancer, immune disturbance
Plain Language Summary
In this study, we compared the incidence of first primary cancers and the incidence of the
same cancers as second primary cancer after squamous cell skin cancer. Skin cancers are
treated by surgery, which is not a risk for second cancer, but skin cancers show immunolo-
gical disturbances that may increase the risk of immune responsive cancers. The results
showed that the incidence ranking of second cancer followed closely the incidence ranking
of these cancers as first cancer. The exceptions were cancers, such as non-Hodgkin lym-
phoma, the incidence of which was increased as second cancer probably due to shared risk
factors, such as immunological disturbances.
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Introduction
Multiple primary cancers are known to be diagnosed in
cancer patients and Vogt et al noted that as far back as
1921 a study reported that 4.5% of cancers appeared to be
“of multiple growth”.1 Multiple primary cancers are con-
sidered when two or more independent tumors are diag-
nosed in an individual, but the exact definitions differ
internationally and nationally.1 Multiple primary cancers
have been of large etiological and clinical interest.2,3
However, as the frequency of new primary cancers drasti-
cally decreases after the second primary cancer (SPC)
much of the literature has focused on SPCs. As examples,
in prostate cancer patients, SPCs account for 11.3% of first
primary cancers (FPCs) and third primaries account for
10.5% of SPCs; in melanoma, the respective proportions
are 13.3% and 17.4% (including multiple melanomas).4,5
In most studies, the incidence of SPC is compared to the
incidence of that cancer as (FPC) and hence the calculated
relative risks (RRs) are used as the outcome measure. In
general, the studies report SPCs with an increased risk, for
example, due to carcinogenic chemo-or radiotherapies.
However, our recent studies on SPC after prostate cancer
suggested that SPCs were “autonomous” from prostate
cancer because the frequencies of SPC correlated with
the frequencies of these cancers as FPC and the risk of
SPC was increased by the familial history of that cancer,
irrespective of prostate cancer.4,6 Moreover, the RRs for
SPCs were equal in screening detected and other prostate
cancer.
We want to address the question of whether the inci-
dence of cancer X differs when it is FPC or SPC after
cancer Y, hypothesizing that a possible difference may
reveal something about cancer etiology. For cancer Y, we
selected skin squamous cell carcinoma (SCC) because
invasive and in situ forms are common thus allowing
high statistical power. We thus assessed the incidence of
cancer X as FPC and as SPC after skin SCC. In Sweden,
invasive SCC ranks second among male and female can-
cers, and in situ SCC has become more common than
invasive SCC.7 Furthermore, these cancers are usually
treated by surgery and the patients are not subjected to
potentially carcinogenic treatments.8 Common risk factors
for SCC include cumulative exposures to ultraviolet (UV)
radiation, viral infections, immune dysfunctions and sun-
sensitive skin.8–10 The role of immune dysfunction is illu-
strated by the high risk of SCC in immune-suppressed
patients.11–13 We used data from the Swedish Cancer
Registry to systematically compare the incidence of FPC
and SPC when SPC was recorded after invasive or in situ
SCC; the 20 most common cancers were analyzed and
their incidence ranking was tested by rank correlation.
While our primary hypothesis was that the ranking
remains uniform, the secondary hypothesis was to gain
etiological clues about cancers that changed their ranking.
Methods
Data of cancer patients were obtained from the Swedish
Cancer Registry, based on the international classification
of diseases 7th revision (ICD-7) and later revisions. The
Registry is population-based and covers practically all
cancers diagnosed in Sweden.14,15 We identified all indi-
viduals who were diagnosed with invasive and in situ SCC
with histological identifiers (WHO/HS/CANC/24.1
Histology Code, “PAD”) 146 and 144, respectively. In
addition, data on most common cancers were retrieved,
including 20 male and 22 female cancers. Upper aerodi-
gestive tract (UAT) included cancers in the mouth, lip,
pharynx and larynx. We followed newly diagnosed
in situ and invasive skin cancer patients for the diagnosis
of any invasive SPC; the follow-up for skin cancers were
started after 1990 from the date of diagnosis until diag-
nosis of SPC, emigration, death, or 31 December 2015,
whichever occurred earliest. A sex-specific age-
standardized (world standard population) incidence rate
for cancer X as SPC was calculated. Similarly, a sex-
specific and age-standardized incidence rate for cancer
X as FPC was calculated. For comparison of incidence
rates, RRs and the corresponding 95% confidence intervals
(95%CIs) were calculated for SPC using the population
incidence of the same FPC as a reference and adjusting the
rates for 5-year age group, 5 year-calendar period, socio-
economic status (6 groups) and place of residence (3
groups) in Poisson regression. Correlation of ranking for
incidence rates between FPC and SPC was tested by
Spearman’s rank correlation rho. All statistical analyses
were done with SAS version 9.4 and R version 3.4. All the
tests were two-tailed and P value below 0.05 was regarded
as statistically significant.
The study was approved by the Regional Ethical
Review Board in Lund, February 6, 2013, without require-
ment for informed consent and was conducted in accor-
dance with the tenets of the Declaration of Helsinki.
People could opt out of the study, which was advertised
in major newspapers, before the project datasets were
constructed. This opting is common in Swedish publically
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collected databases but opting out is utterly rare. The
project datasets are located at the Center for Primary
Health Care Research in Malmö, Sweden.
Results
Among 16.1 million individuals who were followed from
1990 to diagnosis of SPC, emigration, death, or
31 December 2015, and 29,061 men and 23,533 women
developed invasive SCC; 27,842 men and 36,383 women
developed in situ SCC. The total number of 20 other male
cancers was 484,850 and that of 22 female cancers was
452,909. Median (interquartile) age at diagnosis of inva-
sive SCC was 78 (70–84) years for men and 80 (71–87)
for women and that of in situ SCC was 82 (75–87) for men
and 78 (69–84) for women. Median (interquartile) time
from first invasive SCC to SPC was 2 (1–6) years for men
and 2 (1–6) for women, and for in situ SCC, it was 3 (0–7)
for men and 3 (1–7) for women.
Table 1 shows incidence rates of FPC and SPC diag-
nosed after invasive SCC in men. The case numbers, inci-
dence rates for FPC and SPC and the related ranks are listed
in columns 2 to 7, followed by adjusted RR for SPC
compared to FPC. Among ranking, upper aerodigestive
cancer (UAT) climbed from position 11 to position 5 as
SPC. RR for UAT after skin SCC compared to UAT as an
FPC was also the highest (3.79), followed by melanoma
(3.23). Other cancers with RRs over 2.0 were connective
tissue (2.64) and breast (2.62) cancers and non-Hodgkin
lymphoma (NHL 2.37); the RRs over 2.0 were bolded.
RRs for all other cancers were also significantly increased
(95% CIs did not include 1.00), except for myeloma and
Hodgkin lymphoma and for endocrine and thyroid cancers.
The overall RR was 1.47.
The rates of common cancers in women as FPC and
SPC are shown in Table 2 when SPCs were diagnosed
after invasive SCC. Among ranking, melanoma, NHL and
UAT climbed from positions 4, 10 and 17 as FPCs to
respective positions 2, 6 and 8 as SPCs. RRs for these
cancers exceeded 2.0 (2.61, 2.09 and 3.68, respectively).
The RR for Hodgkin lymphoma was 2.20 (0.98–4.93).
RRs for breast, colorectal, lung, endometrial, ovarian,
bladder, female genital and connective tissue cancers and
Table 1 Incidence of Common Cancers as First Primary Cancer and Second Primary Cancer, and Respective Relative Risk (RR) in
Men
First Primary Cancer Second Primary Cancer After Invasive SCC
Cancer Number of
Cases
Standardized Rate
1/100,000
Rank1 Number of
Cases
Standardized Rate
2/100,000
Rank2 RR 95% CI
Prostate 185,081 95.2 1 1483 110.4 1 1.16 1.10 1.22
Colorectum 60,037 32.2 2 545 42.5 3 1.32 1.21 1.44
Lung 41,165 23.5 3 372 40.9 4 1.74 1.57 1.93
Bladder 35,818 18.9 4 374 26.5 7 1.40 1.27 1.55
Melanoma 22,812 14.7 5 355 47.5 2 3.23 2.91 3.60
Leukemia 17,318 11.3 6 180 21.7 8 1.92 1.66 2.23
NHL 18,414 11.3 7 237 26.8 6 2.37 2.08 2.70
Nervous system 14,199 11.1 8 45 15.0 9 1.35 1.01 1.81
Kidney 13,922 8.7 9 98 13.3 10 1.53 1.26 1.87
Stomach 13,800 7.3 10 152 12.4 11 1.70 1.44 1.99
UAT 11,371 7.2 11 195 27.3 5 3.79 3.29 4.38
Liver 10,990 6.3 12 82 8.8 12 1.39 1.12 1.72
Myeloma 7202 4.0 13 52 4.6 14 1.15 0.88 1.51
Endocrine 5558 3.9 14 16 3.9 15 0.99 0.60 1.62
Connective tissue 3564 2.4 15 46 6.3 13 2.64 1.97 3.54
Hodgkin lymphoma 2399 2.0 16 8 3.8 16 1.91 0.95 3.85
Thyroid 2213 1.6 17 10 2.3 18 1.45 0.78 2.71
Small intestine 2423 1.5 18 21 2.5 17 1.65 1.07 2.54
Male genital 1835 1.1 19 22 2.1 19 1.94 1.27 2.96
Breast 803 0.5 20 14 1.3 20 2.62 1.54 4.47
All* 515,982 256.0 – 4662 376.3 – 1.47 1.43 1.51
Notes: *Skin cancer is removed from all cancers; some rare cancers, not listed in Table 1 are included. Bolding shows RRs>2.00.
Abbreviations: SCC, squamous cell carcinoma; NHL, non-Hodgkin lymphoma; UAT, upper aerodigestive tract.
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leukemia were also significant . RRs for six cancers were
below 1.00 but none of these were significant. The overall
RR was 1.37.
The rates after in situ SCC in men are shown in
Supplementary Table 1. All RRs that were over 2.0 in Table
1were over 2.0 in Supplementary Table 1, although someRRs
after in situ SCC were somewhat smaller. RRs for leukemia
(2.13) and Hodgkin lymphoma (2.57) were somewhat higher
and for male genital cancer (1.93) the RRwas equal compared
to the results in Table 1. The only difference to Table 1 was for
male breast cancer, theRRofwhichwasmuch lower, 1.15 (yet
95% CIs overlapped). The overall RR was 1.40.
Female rates after in situ SCC are shown in
Supplementary Table 2. The results were consistent with
data in Table 2: however, the RR of 3.36 for melanoma
was significantly higher than the RR of 2.61 for melanoma
in Table 2. The overall RR was 1.35.
In Table 3 we show results from incidence-ranking
analysis conducted for SPCs following invasive and
in situ SCC in men and women, summarizing the results
from the above tables. Rank correlations were marginally
higher for men than for women and higher after in situ
than after invasive SCC, all correlations were highly sig-
nificant (P~5×10−6).
The results for male RRs are summarized in Figure 1
illustrating the systematic covariation of RRs for cancers
when diagnosed after invasive and in situ SCC. UAT after
Table 2 Incidence of Common Cancers as First Primary Cancer and Second Primary Cancer, and Respective Relative Risk (RR) in
Women
First Primary Cancer Second Primary Cancer After Invasive SCC
Cancer Number of
Cases
Standardized Rate
1/100,000
Rank1 Number of
Cases
Standardized Rate
2/100,000
Rank2 RR 95% CI
Breast 143,819 83.6 1 529 103.7 1 1.24 1.14 1.35
Colorectum 56,198 24 2 354 30.0 3 1.25 1.13 1.39
Lung 31,306 16.4 3 136 22.1 4 1.35 1.14 1.60
Melanoma 23,800 15.2 4 181 39.7 2 2.61 2.25 3.02
Endometrium 28,548 14.7 5 134 19.0 5 1.29 1.09 1.53
Nervous system 16,042 11.5 6 19 7.5 10 0.65 0.41 1.02
Ovary 18,523 11 7 68 15.4 7 1.40 1.10 1.77
Leukemia 13,833 7.9 8 95 13.4 9 1.69 1.38 2.07
Cervix 11,053 7.7 9 19 7.4 11 0.96 0.61 1.51
NHL 15,152 7.6 10 132 15.9 6 2.09 1.76 2.48
Endocrine 11,393 7.2 11 20 5.5 14 0.77 0.49 1.19
Bladder 12,134 5.2 12 83 6.9 12 1.33 1.07 1.65
Kidney 9520 5 13 32 5.0 15 0.99 0.70 1.40
Liver 10,939 4.8 14 52 5.7 13 1.18 0.90 1.55
Thyroid 5758 4.1 15 9 3.3 19 0.81 0.42 1.57
Stomach 8889 3.7 16 50 4.5 16 1.22 0.92 1.61
UAT 6932 3.7 17 105 13.6 8 3.68 3.03 4.47
Myeloma 5898 2.6 18 27 2.6 21 1.00 0.69 1.47
Female genital 4450 1.9 19 44 3.5 18 1.86 1.38 2.51
Connective tissue 2903 1.8 20 17 3.2 20 1.76 1.09 2.84
Hodgkin lymphoma 1934 1.7 21 6 3.7 17 2.20 0.98 4.93
Small intestine 2112 1 22 7 0.8 22 0.83 0.39 1.74
All* 481,702 237.7 – 2371 325.6 – 1.37 1.32 1.43
Notes: *Skin cancer is removed from all cancers; some rare cancers, not listed in Table 2 are included. Bolding shows RRs>2.00.
Abbreviations: SCC, squamous cell carcinoma; NHL, non-Hodgkin lymphoma; UAT, upper aerodigestive tract.
Table 3 Spearman Rank Correlation Between Incidences of the
First Primary Cancer and Second Primary Cancer After Invasive
and in situ SCC
Gender SCC Spearman Rank Correlation
Coefficient (r)
P
Invasive Men 0.95 5.95×10−6
Women 0.90 3.45×10−6
In situ Men 0.96 6.41×10−6
Women 0.94 4.03×10−6
Abbreviation: SCC, squamous cell carcinoma.
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invasive SCC wass a real deviation with highest of all RRs
and the largest difference when diagnosed after invasive
and in situ SCC. Similarly, female data are shown in
Figure 2 confirming the covariation of invasive and
in situ results and the high risk of UAT, especially after
invasive SCC.
Discussion
A novel set of findings was revealed by comparing the
incidence ranking of SPCs appearing after skin SCC to the
ranking of same cancers as FPCs. The ranking of FPC was
largely maintained among SPCs in men and women, with
rank correlations at or above 0.90 and highly significant
P-values. SPCs following in situ SCC showed marginally
higher correlation than SPCs after invasive SCC, and male
correlations were marginally higher than female correla-
tions. The high correlations suggest that skin cancer does
not influence the formation of SPCs and thus SPCs appear
to be autonomous from skin cancer which seems to resem-
ble SPCs after prostate cancer.4,6 The higher correlations
after in situ than invasive SCC may be rationalized by
in situ being a precursor stage of shorter life-span and size
than invasive lesions.8
If ranking was identical for FPC and SPC the correla-
tion would be 1.00. A perfect ranking would be main-
tained if the incidence of all cancers remained stable or
if systematically increased or decreased for all cancers.
The overall RRs were 1.47 (men) and 1.37 (women)
after invasive SCC and 1.40/1.35 after in situ SCC indicat-
ing that incidence levels were generally increased for
SPCs compared to FPCs. The deviation from rho=1.00
indicates deviations in ranking and thus positive or nega-
tive interference of the underlying carcinogenic process
that drives cancer incidence. For individual cancers,
Figure 1 Relative risks (RRs) for second primary cancer in men after invasive and in situ SCC of the skin. The error bars show 95% confidence intervals.
Dovepress Zheng et al
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a positive interference would be shown by an RR>1.00
and a negative one by an RR<1.00. We found no indica-
tion of negative interference as no single RR was signifi-
cantly below 1.00. This is also technically reassuring
because a deficit in reporting of SPCs would also contri-
bute to low RR;16,17 this concurs with data reporting
a generally high coverage of cancers by the Swedish
Cancer Registry.14
Possible causes or contributing factors for SPCs are
many, but probably the most important ones are intensive
medical surveillance after the diagnosis of FPC, therapy
for FPC, shared genetic or non-genetic risk factors
between FPC and SPC and immune dysfunction elicited
by FPC.2,18,19 In the case of skin cancer therapy is not an
issue, but medical surveillance probably is, because SPCs
were diagnosed relatively shortly after skin cancers (2–3
years) which are generally diagnosed in elderly subjects
(median diagnostic ages were 78–82 years in this study).20
However, as practically all cancers reported to the Swedish
Cancer Registry are histologically confirmed, the effect of
medical surveillance would be antedating of diagnoses
rather than introducing wrong diagnoses.
There was ample evidence for non-random positive
interference, which marked a set of particular cancers.
The RRs between incidence rates showed some systematic
changes, replicated between sexes and invasive and in situ
forms, which can be visualized in Figures 1 and 2. Such
consistent changes should offer some etiological clues.
Figure 2 Relative risks (RRs) for second primary cancer in women after invasive and in situ SCC of the skin. The error bars show 95% confidence intervals.
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The increased RRs for melanoma are likely a consequence
of shared risk factors (solar radiation and sensitive skin
type). Melanoma is an immune responsive tumor, as
shown by successes in treatment with checkpoint blocking
agents, and immune mechanisms may also contribute to
melanoma development.21 The increased RRs for NHL
and Hodgkin lymphoma, and cancers of the UAT, connec-
tive tissue and male and female genitals may be explained
by immune dysfunction caused by skin SCC or a shared
host risk factor. These cancers are known to be related to
iatrogenic immune suppression for organ
transplantation.11,12,22-24 UAT and genital cancer are
related to human papilloma virus (HPV) infections,
which are known to be intensified in immunosuppressed
patients.25,26 The large difference for RR in UAT between
invasive and in situ SCC may illustrate the higher level of
immune dysfunction in invasive SCC probably presenting
with chronic inflammation.13 Cervical cancer is another
HPV related cancer but it showed no increase in RR; the
likely reason is its generally earlier onset compared to
SCC. Finally, the intriguingly high RR for male breast
cancer after invasive SCC could be, if not a fortuitous
finding, due to UV-induced chronic inflammation affecting
male breast ductal system which is in intimate contact with
skin, different from the female breast anatomy.
The study has major strengths in being able to use
nationwide and histologically confirmed data on skin
tumors, which are not recorded by most cancer registries.
SPCs are still rare and for some types of SPCs statistical
power was not high. For any benign conditions such as
SCC, particularly in situ SCC, an undefined proportion of
cases may not be reported to the Cancer Registry; how-
ever, the present results were not sensitive to underreport-
ing of FPCs. Nevertheless, reporting of SPC would be
critical to this study. Importantly, the present results tended
to reassuringly indicate that the reporting rate is at the
same level as that for FPCs.
In summary, we found high Spearman rank correlations
between incidences of FPC and SPCs. The results support
the notion that overall skin SCC does not greatly interfere
with the intrinsic carcinogenic process for other cancers.
The main deviations in incidence between FPC and SPC
appeared to be due to shared risk factors or immunological
processes promoting immune responsive cancer types.
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